News | November 21, 2024
Siegfried opens global R&D Center for Drug Substances in Switzerland
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
Subscribe To Our Newsletter & Stay Updated
